Press Release
October 25, 2022

WhizAI Secures $21M in New Funding from Shanda Group and AmerisourceBergen

WhizAI Secures $21M in New Funding from Shanda Group and AmerisourceBergen

Somerset, Oct 25th, 2022 -- WhizAI, the first and only augmented analytics platform purpose-built for the life sciences and healthcare industries, has announced it has completed a new round of funding, bringing total funding since launching in 2017 to $21 million. The company received investment from strategic investors Shanda Group and AmerisourceBergen’s AB Health Ventures, with participation from existing investors like Vertical Venture Partners and Healthy Ventures. 

The new financing builds on a terrific year for WhizAI which included expanding its footprint with new and existing top global pharma clients, forming new strategic partnerships, and adding to its leadership team, the sales and marketing organization, engineering capacity and product capabilities. Earlier this year WhizAI was named by Gartner in five different hype cycles for natural language query, AI in clinical development and augmented analytics for life sciences. In addition, Everest Group named WhizAI a “trailblazer” in their “Life Sciences Commercial Analytics and AI Trailblazers: Top Seven Startups Creating a Buzz in the Life Sciences Commercial Technology Landscape”

“WhizAI began with the vision to democratize business insights for life sciences and healthcare, ensuring analytics is for everyone. Our momentum in 2022 demonstrates that our vision and domain-centric approach is preferred by our clients.” said Rohit Vashisht, Co-Founder and CEO, WhizAI. “We’re excited to see how the market has responded to our vision for analytics to be augmented with artificial intelligence and natural language technology.  With the support of AB Health Ventures and our other investors such as Shanda Group we’re ready to take the next step in bringing actionable insights and ultimately, greater agility, better decision making, and cost savings to our clients’ analytics ecosystem.”

"As the healthcare and pharmaceutical market continue to make major advances in the development of specialty medicines, it’s essential that we’re always thinking about ways to deliver best-in-class solutions that will enhance access to care," said Leslie Donato, EVP and Chief Strategy Officer, AmerisourceBergen. "The analytics-driven approach that WhizAI has pioneered will strengthen product commercialization. We look forward to partnering with WhizAI for this next chapter of growth as the company continues to expand its innovative approach to delivering automated, conversational, and dynamically-generated actionable insights.”

“The future of analytics is business user-oriented, it’s conversational and is augmented with artificial intelligence and natural language technology,” said David Tan, Executive Director, Shanda Group. “WhizAI is at the forefront of this movement, leveraging technology to give insights to business users that help them make better, smarter and faster decisions. We are excited to make this investment leading to the future of a business-focused and dynamic analytic experience for life sciences and healthcare.”

About WhizAI: WhizAI is the first and only AI-powered analytics platform purpose-built for life sciences and healthcare. It puts insights directly into the hands of business users empowering decision-makers to drive more informed and faster business decisions at lower cost. With its deep understanding of the life sciences and healthcare domains and user intent, the platform delivers insights without the delays of traditional BI dashboards. Fast, easy, and scalable, WhizAI is transforming analytics with artificial intelligence optimized for life sciences and healthcare making WhizAI the trusted partner of choice at top global companies. Learn more at

People also viewed